Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HW241045 in Healthy Subjects (Phase Ia)
NCT07448194Phase 1Recruiting
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute
- Start
- Nov 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing HW241045 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 48 hours. Started Nov 2025; status: recruiting.
02
Drugs
HW241045
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07448194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07448194.